Expert Analysis
New Antiretroviral Agents and Insights From Basic Science
Source: CCO Independent Conference Coverage of the 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment*
*CCO is an independent medical education company that provides state-of-the-art
medical information to healthcare professionals through conference coverage and other educational programs.
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
List adverse effects associated with short-term exposure to investigational antiretrovirals in early clinical studies. Describe recent data on the antiviral activity of investigational antiretrovirals in dose-ranging studies. Review findings regarding the efficacy of new and investigational agents in treatment-experienced patients.
Topics covered include:
- New NRTIs in Development
- New NNRTIs in Development
- POWER-1 Study of TMC114/Ritonavir
- Predictors of Response to Tipranavir
- Small-Molecule Entry Inhibitors
- Immunologic and Basic Science Studies
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
CCO Resources
CCO Expert Recap of data from the 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment
|
|